Colorectal cancer screening: the test can be completed in a home kit

Share This Post

The American Cancer Society estimates that more than 97,000 people in the United States will be diagnosed with colorectal cancer this year and will cause approximately 50,600 deaths. It is the third most common cancer in the United States and the second leading cause of cancer death.

Although colorectal cancer screening has been shown to be effective in reducing cancer deaths, researchers report that the number of screeners is too small. The current guidelines of the ACS recommend routine screening for general-risk groups 45 years of age and older, using high-sensitivity fecal examination or structural (visual) examination, and all positive results should be  colonoscopy. Despite these recommendations, the study found significant differences in screening rates, including ethnicity, geographic area, and other socioeconomic factors.

Since colorectal cancer is a preventable disease, efforts are being made throughout the country to increase the screening rate of colorectal cancer, but the screening rate is only about 63%, while the screening rate of low-income and other vulnerable groups is often lower.

The latest research suggests that with stool immunochemical tests, or FIT kits, they can detect blood in stool and common symptoms of colon cancer. The patient can complete the test at home and return it to the provider for analysis. Patients with a positive result of the FIT kit test will be scheduled for colonoscopy.

In the study, 21% of patients who received the FIT kit completed the screening test, and 18 people who completed the FIT test had abnormal results, and 15 of them required colonoscopy. Of the 10 patients who completed the colonoscopy, 1 patient had abnormal results.

The researchers plan to continue to study whether this detection method can be implemented on a larger scale and learn more about cost-effectiveness and how to increase the screening rate of vulnerable groups.

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
CAR T-Cell therapy

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

CAR T cell therapy has transformed cancer treatment, especially in hematological malignancies. Treatment of solid tumors remains challenging due to their immunosuppressive tumor microenvironment. Combination with chemotherapy, immune checkpoint inhibitors, oncolytic viruses, and improved genetic engineering holds promise. Multimodal approaches enhance immune cell infiltration and persistence, raising efficacy. Evolving personalized methods will be instrumental in overcoming solid tumor resistance and improving patient outcomes.

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
CAR T-Cell therapy

How to prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies?

CAR T-cell therapy revolutionized cancer therapy, offering incredible success in the management of B-cell malignancies, but it is associated with severe infection risks secondary to immunosuppression. Preventive measures are pre-infusion screening, vaccination, and antimicrobial prophylaxis. Post-infusion, close surveillance for infection and cytokine release syndrome management are key. Long-term care includes the treatment of hypogammaglobulinemia, revaccination, and patient education. The approach ensures improved outcomes and reduces infection-related complications in patients receiving CD19-targeted CAR T-cell therapy.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟